PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review

被引：6

作者：

Mehta, Prashant ^{[1
]}

Bothra, Sneha J. ^{[2
]}

机构：

[1] Asian Inst Med Sci, Dept Med Oncol Hematol & BMT, Faridabad, India

[2] Act Canc Inst, Dept Med Oncol, New Delhi, India

来源：

ADVANCES IN GENETICS, VOL 108 | 2021年 / 108卷

关键词：

OLAPARIB MAINTENANCE THERAPY; GERMLINE BRCA1/2 MUTATION; POLY(ADP-RIBOSE) POLYMERASE; SYNTHETIC LETHALITY; DOUBLE-BLIND; CHEMOTHERAPY; CARCINOMA; RUCAPARIB; BRCANESS; MONOTHERAPY;

D O I：

10.1016/bs.adgen.2021.08.002

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

There has been a paradigm shift in the management of cancer, with the immense progress in cancer genomics. More and more targeted therapies are becoming available by the day and personalized medicine is becoming popular with specific drugs being designed for selected subgroups of patients. One such new class of targeted drugs in the armamentarium is Poly ADP Ribose Polymerase (PARP) inhibitors (PARPi), which inhibit the enzyme PARP, thus interfering with DNA repair. This strategy utilizes a pre-existing genomic lesion in tumors with homologous recombination repair defects (including BRCA mutations), weakening tumor cells further by blocking the alternate pathway of DNA repair. In this review, we discuss in detail, the evolution, genetics, mechanism of action, mechanism of resistance, indications of use of PARP inhibitors, as well as combination with other agents and future directions.

引用

页码：35 / 80

页数：46

共 50 条

[1] PARP Inhibitors in Ovarian and Other Cancers
Plummer, Ruth
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 283 - 285
[2] The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
Drew, Yvette
Calvert, Hilary
[J]. RECENT ADVANCES IN CLINICAL ONCOLOGY, 2008, 1138 : 136 - 145
[3] PARP Inhibitors in Breast and Ovarian Cancer
Wang, Samuel S. Y.
Jie, Yeo Ee
Cheng, Sim Wey
Ling, Goh Liuh
Ming, Heong Valerie Yue
[J]. CANCERS, 2023, 15 (08)
[4] PARP Inhibitors in Ovarian Cancer: A Review
David M. O’Malley
Thomas C. Krivak
Nashwa Kabil
Jiefen Munley
Kathleen N. Moore
[J]. Targeted Oncology, 2023, 18 : 471 - 503
[5] PARP Inhibitors in Ovarian Cancer: A Review
O'Malley, David M.
Krivak, Thomas C.
Kabil, Nashwa
Munley, Jiefen
Moore, Kathleen N.
[J]. TARGETED ONCOLOGY, 2023, 18 (04) : 471 - 503
[6] PARP inhibitors in the treatment of ovarian cancer: a review
Washington, Christina R.
Moore, Kathleen N.
[J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2021, 33 (01) : 1 - 6
[7] PARP inhibitors for all ovarian cancers
Javier Carmona
[J]. Nature Medicine, 2019, 25 : 1647 - 1647
[8] PARP inhibitors for hereditary breast cancer with germline BRCA mutation
Im, Seock-Ah
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S423 - S423
[9] Hereditary breast and ovarian cancers
Gevensleben, H.
Serce, N.
Buettner, R.
[J]. PATHOLOGE, 2010, 31 (06): : 438 - 444
[10] Hereditary breast and ovarian cancers
Carroll, June C.
Cremin, Carol
Allanson, Judith
Blaine, Sean M.
Dorman, Heather
Gibbons, Clare A.
Grimshaw, Jeremy
Honeywell, Christina
Meschino, Wendy S.
Permaul, Joanne
Wilson, Brenda J.
[J]. CANADIAN FAMILY PHYSICIAN, 2008, 54 (12) : 1691 - 1692

← 1 2 3 4 5 →